$KALY and GNBT could impact Motley Fool’s 2019 prediction for GWPH. See Motley Fool’s prediction #4 of 7 for cannabis stocks in 2019:
4. First U.S. plant-based cannabinoid drug is a big hit, Big Pharma execs injure themselves after slapping foreheads in regret
Despite some nattering negativism by skeptics, GW Pharmaceuticals’ (NASDAQ: GWPH) Epidiolex, the first plant-based cannabinoid drug approved in the U.S., becomes a smashing commercial success. Even pessimistic analysts project that Epidiolex likely will become a blockbuster within a few years.
As Epidiolex sales steadily increase, several renowned Big Pharma executives are forced to receive medical care for injuries received from slapping themselves on the foreheads in regret. These slaps stem from the executives reading the histories of their companies marketing cannabis-based drugs in the early 20th century. (Source: Motley Fool)
Keep an eye on KALY and GNBT. Both are showing characteristics of entry level prices you might regret missing.
Learn more about Kali, Inc. at http://www.kali-extracts.com.
Learn more about Generex at http://www.generex.com.